Inventor · disambiguated record
Rui Zhu
Also filed as: ZHU RUI
16 granted patents·21 pending applications·47 citations·filing 2017–2025
91Inventor score
Files withARROWHEAD PHARMACEUTICALS INC26ADARX PHARMACEUTICALS INC7UNIV SHAANXI TECHNOLOGY2ADARX PHARMACEUTICAL INC1BEIJING WANTAI BIOLOGICAL PHARMACY ENTPR CO LTD1
Top patents by PatentIndex Score
37 records- 0196US10450565B2Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Oct 22, 2019·15 cites·39 claims
- 0295US11884920B2Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Jan 30, 2024·2 cites·21 claims
- 0394US11517584B2RNAi agents for Hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Dec 6, 2022·2 cites·58 claims
- 0494US11214801B2RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Jan 4, 2022·3 cites·30 claims
- 0593US10597657B2RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Mar 24, 2020·6 cites·51 claims
- 0692US11590156B2RNAi agents for hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Feb 28, 2023·2 cites·37 claims
- 0792US11203756B2Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Dec 21, 2021·5 cites·25 claims
- 0892US10780108B2RNAi agents for Hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Sep 22, 2020·5 cites·67 claims
- 0985US12365899B2RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Jul 22, 2025·0 cites·22 claims
- 1084US2024141351A1Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1183US10995335B2RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted May 4, 2021·3 cites·19 claims
- 1282US11597701B2Integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Mar 7, 2023·2 cites·24 claims
- 1381US10590416B2RNAi agents for inhibiting expression of alpha-ENaC and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Mar 17, 2020·1 cites·52 claims
- 1480US2023355651A1Rnai agents for hepatitis b virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1577US2022064646A1RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1676US11492624B2RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1ARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Nov 8, 2022·1 cites·21 claims
- 1771US2022090077A1RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1869US11214802B2RNAi agents for inhibiting expression of alpha-ENaC and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Jan 4, 2022·0 cites·42 claims
- 1967US2024076270A1Integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2065US2024150436A1Application of MmPI in Preparation of Trypsin InhibitorsUNIV SHAANXI TECHNOLOGY·Filed 2023·Application pending·0 cites
- 2165US2024150435A1Application of MmBBK2 in Preparation of Trypsin and Chymotrypsin InhibitorsUNIV SHAANXI TECHNOLOGY·Filed 2023·Application pending·0 cites
- 2264US2019255091A1RNAi AGENTS FOR HEPATITIS B VIRUS INFECTIONARROWHEAD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2363US2025388900A1Compositions and Methods for Inhibition of Factor XII Gene ExpressionARROWHEAD PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2462US2025073256A1Prekallikrein-modulating compositions and methods of use thereofADARX PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2561US12042509B2Prekallikrein-modulating compositions and methods of use thereofADARX PHARMACEUTICALS INC·Filed 2022·Granted Jul 23, 2024·0 cites·36 claims
- 2661US2021238602A1RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of UseARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2761US2024041913A1Angiotensinogen-modulating compositions and methods of use thereofADARX PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2860US2023013022A1RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2958US2022152079A1Methods For The Treatment Of APOC3-Related Diseases And DisordersARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3056US2025312367A1Oligonucleotides having a synthetic backbone and synthesis thereofADARX PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3156US2025161459A1Trkb ligand conjugated compounds and uses thereofADARX PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3254US2024401045A1Angiotensinogen-modulating compositions and methods of use thereofADARX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3353US2024350615A1General affinity epitope polypeptide for human rhinovirus, and antibody and uses thereofBEIJING WANTAI BIOLOGICAL PHARMACY ENTPR CO LTD·Filed 2022·Application pending·0 cites
- 3452US2019382763A1Compositions and Methods for Inhibition of Factor XII Gene ExpressionARROWHEAD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3551US12221610B2RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Feb 11, 2025·0 cites·20 claims
- 3650US2024083934A1N-acetylgalactosamine (galnac)-derived compounds and oligonucleotidesADARX PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3748US2023272391A1Adar dependent editing compositions and methods of use thereofADARX PHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Rui Zhu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →